UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
|
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
|
November
6, 2009
|
|
(Exact
name of registrant specified in its charter)
|
Delaware
|
1-32302
|
41-1350192
|
(State
or other jurisdiction of incorporation)
|
(Commission
File Number)
|
(I.R.S.
Employer Identification No.)
|
|
250
Phillips Blvd., Suite 290, Ewing, NJ
|
08618
|
(Address
of principal executive offices)
|
(Zip
Code)
|
Registrant’s
telephone, including area code:
|
(609)
359-3020
|
|
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the Registrant under any of the following provisions (see General Instruction A.2.
below):
□ Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
□ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
□ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
□ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item
8.01. Other
Events.
On November 6, 2009, Antares Pharma,
Inc.’s (“Antares”) wholly owned subsidiary, Antares Pharma AG (the “Company”)
entered into an Asset Purchase Agreement (the “Purchase Agreement”) with Ferring
Allschwil AG (“Ferring”). Pursuant to the terms and conditions of the
Purchase Agreement, Ferring will purchase from the Company all of the assets,
including equipment, fixtures, fittings and inventory, located at the Company’s
research and development facility located in Allschwil, Switzerland (the
“Facility”). Further pursuant to the terms and conditions of the
Purchase Agreement, Ferring will assume the contractual obligations related to
the Facility, including the real property lease for the Facility, and will
continue to employ the employees working at the Facility.
Also on November 6, 2009, in tandem
with the execution of the Purchase Agreement, Antares Pharma, Inc.’s wholly
owned subsidiary, Antares Pharma IPL AG, entered into an Exclusive License
Agreement with Ferring in the ordinary course of business, which agreement
relates to a license under Antares’ patents and transfer of know-how for its
transdermal gel technology for certain pharmaceutical products.
A copy of the Antares press release
announcing the above-described transactions is attached as Exhibit 99.1 to this
Current Report on Form 8-K and is incorporated by reference into this Item
8.01.
Item
9.01. Financial
Statements and Exhibits.
(d) Exhibits.
Exhibit
Number
|
Description
|
99.1
|
Press
Release, dated November 11, 2009.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
|
ANTARES
PHARMA, INC.
|
|
|
|
Date:
|
|
|
By:
|
|
|
|
Name:
Dr. Paul K. Wotton
Title:
President and Chief Executive
Officer
|
EXHIBIT
INDEX
Exhibit
Number
|
Description
|
99.1
|
Press
Release, dated November 11, 2009.
|